{"id":"W4324132274","doi":"10.1016/s0960-9776(23)00123-6","title":"P004 Pyrotinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer : a multicenter, open-label, phase 2 trial","year":2023,"lang":"en","type":"article","venue":"The Breast","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Seagen (Canada)","funders":"","keywords":"Medicine; Trastuzumab; Open label; Oncology; Adjuvant; Breast cancer; Internal medicine; Adjuvant therapy; Clinical trial; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001068798,0.0006426261,0.0006588374,0.0002566702,0.0002091348,0.0007008594,0.0004635171,0.0007518066,0.006328191],"category_scores_gemma":[0.000924456,0.0001539427,0.0005608981,0.0002879666,0.0003776665,0.0005966802,0.0001952624,0.001478836,0.0007386369],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005416196,"about_ca_system_score_gemma":0.0009215447,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004737789,"about_ca_topic_score_gemma":0.001476872,"domain_scores_codex":[0.9997479,0.0001426225,0.00001015047,0.00002754671,0.00002711294,0.00004467036],"domain_scores_gemma":[0.999687,0.00007787885,0.00007198806,0.00002282564,0.0000190442,0.0001212994],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7390445,0.03449918,0.007052438,0.0007529947,0.001063601,0.0002530233,0.000133678,0.001947031,0.01465528,0.0004451414,0.005691377,0.1944618],"study_design_scores_gemma":[0.67193,0.3022167,0.01635785,0.00005481068,0.00037926,0.0002392206,0.00005949064,0.001571832,0.002417027,0.0004017133,0.004348841,0.00002329354],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9925598,0.00133866,0.0002928442,0.0006034385,0.0001286343,0.001183226,0.0008900765,0.00007802943,0.002925427],"genre_scores_gemma":[0.9881919,0.00123472,0.001202944,0.0007732635,0.0002316293,0.001266273,0.001847195,0.00001789325,0.005234121],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006328191,"threshold_uncertainty_score":0.0211699,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04864517656838026,"score_gpt":0.3922865478377956,"score_spread":0.3436413712694154,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}